Engineers Gate Manager LP Immuno Gen, Inc. Transaction History

Engineers Gate Manager LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $1.09 Million - $2.63 Million	87,651 New	87,651 $2.6 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $91,956 - $132,803	20,526 New	20,526 $98,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $275,940 - $504,576	-87,600 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $125,244 - $219,912	29,400 Added 50.52%	87,600 $417,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $159,125 - $251,250	33,500 Added 135.63%	58,200 $432,000
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $112,864 - $148,162	-22,483 Reduced 47.65%	24,700 $140,000
Q2 2021 Aug 16, 2021	SELL	$5.79 - $8.6 $42,944 - $63,786	-7,417 Reduced 13.58%	47,183 $311,000
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $30,550 - $49,491	4,700 Added 9.42%	54,600 $442,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $184,630 - $382,234	49,900 New	49,900 $322,000
Q3 2020 Nov 16, 2020	SELL	$3.45 - $4.89 $41,055 - $58,190	-11,900 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$3.32 - $5.34 $39,508 - $63,546	11,900 New	11,900 $55,000
Q1 2018 May 07, 2018	SELL	$6.7 - $12.95 $155,440 - $300,440	-23,200 Closed	0 $0
Q4 2017 Feb 01, 2018	BUY	$5.07 - $7.92 $117,624 - $183,744	23,200	23,200 $149,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.